Rockwell Medical (RMTI)

Rockwell Medical is a biopharmaceutical company dedicated to transforming anemia management in a wide variety of therapeutic areas and across the globe, improving the lives of very sick patients. The Company's initial focus is the treatment of anemia in end-stage kidney disease (ESKD). Rockwell Medical's exclusive renal drug therapies, Triferic (ferric pyrophosphate citrate) Dialysate and Triferic AVNU (ferric pyrophosphate citrate injection), are the only FDA-approved therapeutics indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.

Company profile

Russell Ellison
Fiscal year end
Former names
Rockwell Transportation, Inc. • Rockwell Medical India Private Limited ...
IRS number
SEC advisor number
FINRA CRD number
$234.04M (as of 4 Sep 20)
2,081 (as of 4 Sep 20)
13 (3 investment advisory or research)
Rockwell Medical
MI 48393
Office hours
Monday - Friday, MO - THU: 8 A.M. - 6 P.M. & FRI : 8 A.M. - 12 P.M.


Owner Title From %Ownership
Richmond, David, Scott President 09/2011 50-75%
Curfman, Matthew, Jeremy Senior Vice President of Investment Services 09/2011 10-25%
Pirner, Gary, Matthew Chief Compliance Officer 12/2018 < 5%

RMTI stock data

Investment data

Data from SEC filings
Securities sold
Number of investors
Regulatory AUM / Assets Under Management
Number of accounts
Number of employees


15 Aug 22
18 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 30.78M 30.78M 30.78M 30.78M 30.78M 30.78M
Cash burn (monthly) (no burn) 133.17K 1.49M 2.2M 1.97M 2.65M
Cash used (since last report) n/a 219.34K 2.46M 3.63M 3.24M 4.37M
Cash remaining n/a 30.56M 28.32M 27.15M 27.54M 26.41M
Runway (months of cash) n/a 229.5 19.0 12.3 14.0 10.0

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jul 22 Mark Strobeck Stock Option Common Stock Grant Acquire A No No 1.28 400,000 512K 400,000
7 Jun 22 Allen Nissenson Common Stock Grant Acquire A No No 0 25,000 0 99,488
7 Jun 22 Andrea Heslin Smiley Common Stock Grant Acquire A No No 0 25,000 0 93,601
7 Jun 22 Cooper John G Common Stock Grant Acquire A No No 0 25,000 0 130,879
13F holders Current Prev Q Change
Total holders 59 62 -4.8%
Opened positions 8 8
Closed positions 11 10 +10.0%
Increased positions 16 7 +128.6%
Reduced positions 13 19 -31.6%
13F shares Current Prev Q Change
Total value 44.44M 45.27M -1.8%
Total shares 24.19M 23.64M +2.4%
Total puts 0 11.2K EXIT
Total calls 100.9K 16.3K +519.0%
Total put/call ratio 0.7
Largest owners Shares Value Change
Richmond Brothers 6.9M $3.24M -1.8%
CVI Investments 4.91M $4.96M 0.0%
Perkins Capital Management 4.13M $1.95M +39.7%
Vanguard 2.95M $1.39M -15.4%
BLK Blackrock 960.83K $453K +0.1%
Millennium Management 803.42K $379K +27.1%
Geode Capital Management 678.44K $319K 0.0%
Verdence Capital Advisors 535.59K $252K +20.8%
Renaissance Technologies 281.23K $133K +24.7%
SkyOak Wealt 215.44K $102K -9.3%
Largest transactions Shares Bought/sold Change
Perkins Capital Management 4.13M +1.17M +39.7%
Vanguard 2.95M -538.15K -15.4%
VIRT Virtu Financial 0 -179.07K EXIT
Millennium Management 803.42K +171.23K +27.1%
Richmond Brothers 6.9M -126.29K -1.8%
Verdence Capital Advisors 535.59K +92.05K +20.8%
Susquehanna International 121.5K +91.3K +302.4%
Jane Street 0 -81.03K EXIT
TROW T. Rowe Price 192.09K -73.8K -27.8%
Renaissance Technologies 281.23K +55.7K +24.7%

Financial report summary

Management Discussion
  • During the year ended December 31, 2021, our net sales were $61.9 million compared to net sales of $62.2 million during the year ended December 31, 2020. Net sales of hemodialysis concentrates to dialysis providers and distributors in the United States and abroad were $60.8 million for the year ended December 31, 2021 compared to $61.1 million for the year ended December 31, 2020. Net sales of Triferic (dialysate) remained flat at approximately $1.1 million for the years ended December 31, 2021 and 2020. On April 6, 2022, the Company and DaVita entered into an amendment (the "DaVita Amendment") to the Products Purchase Agreement, dated July 1, 2019 under which the Company supplies DaVita with certain dialysis concentrates. Under the DaVita Amendment, the Company and DaVita agreed to a price increase, effective May 1, 2022. Based the DaVita Amendment and assuming steady sales volumes, the Company expects a double digit increase in concentrates revenue year-over-year.

Content analysis

H.S. sophomore Avg
New words: accrual, acid, adulteration, advertising, agency, alternative, appointed, appointment, apportionment, ATM, attributable, batch, bicarbonate, blood, built, center, Certificate, Chile, clause, compliant, consumed, contamination, correction, corrective, covid, criminal, deducting, deep, defect, degradation, denial, Department, direct, director, disagreement, dispute, earlier, embedded, employee, enforcement, equivalent, expend, federal, freestanding, GMP, halt, Hedging, holder, host, indemnification, inspection, inspector, Instruction, instrument, interruption, Iowa, John, longstanding, low, macromolecular, majeure, mandatorily, member, membership, method, mission, move, moving, negligible, nominated, occupied, opportunity, packaging, penalty, permanent, Peru, PIPE, Placement, prefunded, premarket, produce, promotion, promptly, proper, prosecution, rationalizing, reappointed, reappointment, recall, redeemable, redeemed, redemption, redemptive, repeated, RRA, sampling, secondary, seizure, settlement, shifting, single, slowdown, source, spend, state, storage, stored, Subtopic, suspension, timeline, Topic, unexpected, uninterrupted, variety, voluntary, wake, withdrawal
Removed: added, alliance, begin, biggest, biopharmaceutical, brought, bundled, capitated, challenged, combined, compelling, comprised, computed, deficit, demonstrating, dependability, dilute, disseminated, earned, employ, exposure, flooding, freezing, generate, generating, generation, grow, growing, guide, identified, Importantly, improved, inception, inclusion, incorporated, increasing, initiate, investigating, lead, located, maintenance, manufactured, Medicare, medium, notwithstanding, older, partnership, path, placebo, planning, population, practice, preliminarily, procedure, profile, real, reduce, reference, reimbursed, responsible, safe, saving, sector, segment, shared, showing, sized, small, solid, study, surge, synergistic, team, transformative, trend, unit, utilize